ACTRN12619001138178招募中未知
Kisqali Access Registry for Metastatic Breast Cancer in Australia
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Female
入选标准
- •Patients who meet the following inclusion criteria are eligible for the study:
- •Age is 18 or over
- •Patients with metastatic or advanced HR positive, HER2 –ve breast cancer who have received combination treatment with ribociclib and an aromatase inhibitor as part of the Novartis ribociclib MAP/SPARK program between the period of 1 May 2017 to 30 June 2018
排除标准
- •Patients who have opted out of data collection will be excluded from the study.
研究者
相似试验
招募中
不适用
Kidney cancer treatment & outcome study.CTRI/2012/11/003147Indian Cooperative Oncology Network100
招募中
不适用
Breast Cancer Registry to collect epidemiological data, treatment patterns & outcomes of breast cancer patients in IndiaCTRI/2014/09/004972Dr Vinod Raina1,200
已完成
不适用
Bone Scan Index for Breast Cancer Bone MetastasisPatients with breast cacner and bone metastasisJPRN-UMIN000016868CSPOR-BC200
尚未招募
Unknown
isting of all cancer patients at Balco Medical Centre.CTRI/2024/07/071650ICMR-NCDIR
已完成
不适用
Breast Cancer Care for patients with metastatic diseaseC50C76C77C78C79C80Malignant neoplasm of breastMalignant neoplasm of other and ill-defined sitesSecondary and unspecified malignant neoplasm of lymph nodesSecondary malignant neoplasm of respiratory and digestive organsSecondary malignant neoplasm of other and unspecified sitesMalignant neoplasm, without specification of siteDRKS00013726niversitätsklinikum Würzburg, Frauenklinik und Poliklinik31